|
Ifinatamab Deruxtecan Clinical Trials
8 actively recruiting trials across 5 locations
No change since August 2026
Also known as: DS-7300a, I-DXd, I-DXd, MK-2400, DS-7300a, MK-2400
Pipeline
Phase 2: 1Phase 3: 3Phase 1/2: 4
Top Sponsors
- Merck Sharp & Dohme LLC4
- Daiichi Sankyo4
Indications
- Cancer8
- Lung Cancer3
- Liver Disease1
- Castration-Resistant Prostatic Cancer1
- Recurrent or Metastatic Solid Tumors1
Los Angeles, California3 trials
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
UCLA Hematology & Oncology ( Site 0003)
Phase 1/2
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Children's Hospital Los Angeles ( Site 4006)
Phase 1/2
Phoenix, Arizona2 trials
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Mayo Clinic in Arizona - Phoenix ( Site 0044)
Phase 3
Birmingham, Alabama1 trial
Springdale, Arkansas1 trial
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Highlands Oncology Group
Phase 3
Lexington, Kentucky1 trial
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
University of Kentucky Chandler Medical Center ( Site 0019)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.